COLL Financials: Revenue Breakdown, Margins & Competitor Comparison
This article analyzes Collegium Pharmaceutical Inc's (COLL) financials, detailing its revenue breakdown, profitability, and market position. Nucynta IR is the largest revenue contributor, and the company demonstrates strong gross and operating margins. COLL is benchmarked against competitors EYPT and SVRA to illustrate its financial performance within the Pharmaceuticals industry.
Collegium Pharmaceutical (COLL) Valuation Check After Recent Share Price Pullback
Collegium Pharmaceutical (COLL) has experienced a significant share price pullback, down 19% over the past month and 29% over the past three months. Despite this, the current share price of $32.31 is estimated to be undervalued by approximately 83% compared to an intrinsic value of $54.17. This valuation is supported by its differentiated pain portfolio and the increasing regulatory emphasis on abuse-deterrent opioid options, though risks like generic competition and reliance on a maturing portfolio exist.
Collegium (COLL) EVP has 8,840 shares withheld for RSU tax payment
Collegium Pharmaceutical EVP David Dieter reported a routine share disposition where 8,840 shares of common stock were withheld at $35.72 per share to cover tax obligations upon the vesting of restricted stock units. This non-market transaction resulted in Dieter directly holding 68,231 shares of Collegium Pharmaceutical common stock. The SEC Form 4 filing clarified that this was a tax-withholding disposition, not an open-market sale.
Collegium Pharmaceutical (COLL) Valuation Check After Recent Share Price Pullback
Collegium Pharmaceutical (COLL) has experienced a significant share price pullback, dropping 19% in the last month and 29% over three months, raising questions about its valuation. Despite this, Simply Wall St's analysis suggests the company is currently undervalued by about 40.4%, with a fair value of $54.17 compared to its current price of $32.31. The valuation is based on its differentiated pain portfolio and potential for profit expansion, though risks like generic competition and reliance on a maturing portfolio exist.
GE HealthCare and Collegium Pharmaceutical Stocks Trade Down, What You Need To Know
GE HealthCare and Collegium Pharmaceutical stocks, among others, experienced a sell-off following reports that the U.S. might impose up to 100% tariffs on imported branded and patented drugs from companies that haven't negotiated lower prices. GE HealthCare (NASDAQ: GEHC) fell 2.7% and Collegium Pharmaceutical (NASDAQ: COLL) dropped 3%. Collegium Pharmaceutical has shown volatility, and despite a recent gain due to easing crude oil prices, its shares are down 28.9% year-to-date.
Collegium Pharmaceutical Acquires AZSTARYS for $650M
Collegium Pharmaceutical Inc. has agreed to acquire AZSTARYS from Corium Therapeutics Holdings for $650 million cash, plus potential earn-out considerations. This acquisition aims to diversify Collegium's revenue beyond pain medicines and strengthen its presence in the ADHD market. The deal is expected to contribute to Collegium's revenue base through the late 2030s and lead to expanded margins and higher operating leverage.
Collegium Pharma Executive David Dieter Sells Shares in March 2026 - News and Statistics
David Dieter, EVP and General Counsel at Collegium Pharmaceutical, sold 6,224 shares of company stock for $228,110 on March 9, 2026. This transaction was part of a pre-planned trading arrangement established in December 2025 and reduced his direct holdings by 6.40% to 91,047 shares. Collegium Pharmaceutical specializes in pain management therapies, particularly abuse-deterrent opioid formulations.
Wedge Capital Management L L P NC Acquires New Stake in Collegium Pharmaceutical, Inc. $COLL
Wedge Capital Management L L P NC has acquired a new stake of 58,261 shares in Collegium Pharmaceutical (NASDAQ:COLL), valued at approximately $2.697 million, representing about 0.18% ownership. This comes as Collegium Pharmaceutical reported Q4 earnings per share of $2.04, missing estimates, while revenue increased by 12.9% year-over-year. The company currently holds a "Moderate Buy" consensus rating from analysts with a target price of $53.40, despite recent insider selling by two executives.
COLL SEC Filings - Collegium Pharmaceutical Inc 10-K, 10-Q, 8-K Forms
This page provides access to Collegium Pharmaceutical Inc. (COLL) SEC filings, including annual 10-K, quarterly 10-Q, and material event 8-K forms, offering detailed financial and governance information. Recent filings include a new $150 million stock repurchase program authorized by the board, effective immediately through December 31, 2026. These documents are crucial for investors to understand the company's financial health, risk factors, and corporate actions.
Is It Time To Reassess Collegium Pharmaceutical (COLL) After The Recent Share Price Pullback?
Collegium Pharmaceutical (COLL) has experienced a 26% share price decline over 30 days despite strong longer-term returns, prompting a reassessment of its value. A Discounted Cash Flow (DCF) analysis suggests the stock is 82.2% undervalued, with an intrinsic value of $187.83 per share compared to its current $33.42. Additionally, the company's P/E ratio of 16.88x is in line with its industry and below its peer group, and also below Simply Wall St's calculated "Fair Ratio" of 23.15x, further indicating undervaluation.
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has received a "Moderate Buy" consensus recommendation from seven analysts, with an average 12-month price target of $53.40. Despite this, there have been significant insider sales from two executive VPs in March, and the company missed its quarterly EPS and revenue estimates, with the stock currently trading well below its moving averages. Several hedge funds have recently adjusted their holdings in the company.
Is It Time To Reassess Collegium Pharmaceutical (COLL) After The Recent Share Price Pullback?
Collegium Pharmaceutical (COLL) has experienced a 26% share price decline over the last month despite positive long-term returns. A Discounted Cash Flow (DCF) analysis suggests the stock is 82.2% undervalued, with an estimated intrinsic value of $187.83 per share compared to its current $33.42. The company's P/E ratio of 16.88x is in line with its industry average and below its "Fair Ratio" of 23.15x, further indicating it may be undervalued.
Vanguard disaggregates holdings; reports 0 shares in Collegium (COLL)
Vanguard has reported zero beneficial ownership of Collegium Pharmaceutical Inc. (COLL) common stock following an internal realignment. This change is due to certain Vanguard subsidiaries now reporting their ownership separately, as per SEC Release No. 34-39538. The amendment, a SCHEDULE 13G/A filing, indicates Vanguard itself no longer holds voting or dispositive power over COLL shares.
Collegium Pharmaceutical, Inc. $COLL Shares Bought by Assenagon Asset Management S.A.
Assenagon Asset Management S.A. significantly increased its stake in Collegium Pharmaceutical (NASDAQ:COLL) by 161.6% in the fourth quarter to 511,698 shares, valued at approximately $23.7 million. Despite insider selling and missing Q4 earnings and revenue estimates, the company's revenue grew by 12.9% year-over-year, and analysts maintain a "Moderate Buy" rating with a consensus price target of $53.40. Other institutional investors also adjusted their holdings in COLL during recent quarters.
Collegium Pharmaceutical, Inc. (COLL) to Present 9 Pain Studies at PAINWeek 2025
Collegium Pharmaceutical, Inc. (COLL) is scheduled to present nine scientific posters related to pain management at the PAINWeek 2025 National Conference, held in Las Vegas, Nevada, from September 5-8, 2025. These presentations will include new data on claims analyses from the IQVIA PharMetrics® Plus database concerning Xtampza® ER (oxycodone extended-release), as well as research on chronic pain, opioid use, and the importance of medication adherence.
Collegium Pharmaceutical, Inc. (COLL) to Present 9 Pain Studies at PAINWeek 2025
Collegium Pharmaceutical, Inc. (COLL) is scheduled to present nine abstracts related to pain management at PAINWeek 2025. These presentations will cover studies on chronic pain, opioid use disorder treatments, and the company's product Xtampza ER, highlighting its commitment to addressing critical aspects of pain and addiction.
Collegium Pharmaceutical EVP Sells Nearly 50,000 Shares Worth $2 Million
Collegium Pharmaceutical's EVP and Chief Commercial Officer, Scott Dreyer, sold 49,976 shares of company stock for approximately $2.02 million on March 3, 2026. This sale, which reduced his direct holdings by over 41%, was executed under a Rule 10b5-1 trading plan established in September 2025, indicating it was a pre-scheduled liquidity event rather than a lack of confidence in the company. Despite the sale, Dreyer still retains a significant stake, and Collegium Pharmaceutical recently reported strong revenues and announced a major acquisition, suggesting a positive outlook.
Collegium Pharmaceutical, Inc. (COLL) Discusses Acquisition of AZSTARYS to Expand ADHD Portfolio and Accelerate Growth - Slideshow (NASDAQ:COLL)
Collegium Pharmaceutical, Inc. (COLL) has announced the acquisition of AZSTARYS, a move aimed at expanding its ADHD portfolio and accelerating growth. The company published a slide deck discussing this event, which was reported by Seeking Alpha's transcripts team. This acquisition is expected to bolster Collegium's position in the ADHD market.
Collegium Pharmaceutical (COLL) Valuation Check After Recent Share Price Volatility
Collegium Pharmaceutical (COLL) has experienced recent share price volatility, with a 2.4% daily decline and a 21% drop over the past month, despite a 17.9% total return over the past year. Analysts project the company to be 34.2% undervalued, with a fair value of $53.83 per share, primarily due to its differentiated pain portfolio and anticipation of a shift in market sentiment. However, the valuation could be impacted by potential generic competition and rising operating costs.
Collegium Pharmaceutical (COLL) Valuation Check After Recent Share Price Volatility
Collegium Pharmaceutical (COLL) has experienced stock price volatility, with recent declines offset by a stronger long-term return. Despite this, the company is considered undervalued by Simply Wall St, with a fair value of $53.83 compared to its current $35.44 trading price, mainly due to its differentiated pain portfolio and expected margin improvements. Investors are urged to consider potential risks like patent expirations and operating costs, alongside the company's P/E ratio, which is slightly above the industry average but below its peer average.
Collegium Pharmaceutical Expands ADHD Portfolio With AZSTARYS And Valuation Gap
Collegium Pharmaceutical (COLL) has acquired AZSTARYS, expanding its ADHD product portfolio and securing longer-term exclusivity for its offerings. The deal is expected to be immediately accretive to adjusted EBITDA. Despite a recent decline in stock momentum, the company's valuation appears significantly below analyst targets and an estimated fair value according to Simply Wall St.
Insider Selling: Collegium Pharmaceutical (NASDAQ:COLL) EVP Sells 13,976 Shares of Stock
Collegium Pharmaceutical (NASDAQ:COLL) EVP David Dieter sold 13,976 shares of company stock for approximately $488,042, reducing his stake by 15.35%. This sale follows the announcement of Collegium's acquisition of AZSTARYS, a deal expected to add significant revenue but also increase the company's debt and financial risk. The company recently missed Q4 earnings estimates, and its stock has traded down amidst these developments.
Collegium (NASDAQ: COLL) EVP trades 13,976 shares under 10b5-1 plan
David Dieter, EVP and General Counsel of Collegium Pharmaceutical, Inc. (NASDAQ: COLL), sold 13,976 shares of common stock on March 18, 2026. The transaction was executed at a weighted average price of $34.9241 per share under a pre-arranged Rule 10b5-1 trading plan. Following this sale, Dieter directly holds 77,071 shares of Collegium common stock.
Collegium Pharmaceuticals: Another M&A Episode Adds To An Intriguing Case (NASDAQ:COLL)
Collegium Pharmaceutical recently announced a $650 million acquisition of AZSTARYS to expand its ADHD portfolio, aiming for $50 million in additional 2026 H2 revenue and $50 million in annual synergies. Despite strong margins and earnings, the company trades at low multiples due to patent expiry and rapid drug portfolio runoff concerns. The deal increases net leverage beyond $1 billion, and while the valuation appears undemanding, the ambiguity of new asset contributions keeps conviction challenged.
Collegium Pharmaceutical stock faces scrutiny amid opioid market shifts and regulatory pressures
Collegium Pharmaceutical (ISIN: US19459E1029) is facing investor scrutiny due to evolving U.S. opioid regulations, increasing competition in pain management, and DEA quota cuts. Despite a 5% increase in net product revenues for Xtampza ER in Q4 2025 and 17% total revenue growth for 2025, shares have seen slight dips amid concerns over generic competition and regulatory probes. The company is actively developing new abuse-deterrent formulations and exploring potential EU licensing deals, but regulatory hurdles and market shifts, which mirror trends in DACH markets, remain key challenges.
Pharma M&A Roundup: Novartis to Acquire Pan-Mutant-Selective PI3Kα Inhibitor from Synnovation Therapeutics, Collegium to Acquire Azstarys from Corium Therapeutics
Novartis is set to acquire SNV4818, a pan-mutant-selective PI3Kα inhibitor, from Synnovation Therapeutics for up to $3 billion to strengthen its breast cancer pipeline. Concurrently, Collegium Pharmaceutical will acquire Azstarys, an ADHD treatment from Corium Therapeutics, for $650 million cash plus potential milestones. These acquisitions highlight ongoing consolidation in the oncology and CNS therapeutic areas, with both companies leveraging strategic deals to enhance their portfolios and drive growth.
Collegium Pharmaceutical Expands ADHD Portfolio With AZSTARYS And Valuation Gap
Collegium Pharmaceutical (NasdaqGS:COLL) has acquired AZSTARYS, a move that significantly expands its ADHD portfolio and secures longer-term product exclusivity for its ADHD offerings. This transaction is expected to be immediately accretive to adjusted EBITDA. The acquisition positions Collegium to navigate competitive pressures in the branded drug market by adding a differentiated ADHD asset.
Needham & Company LLC Reiterates Buy Rating for Collegium Pharmaceutical (NASDAQ:COLL)
Needham & Company LLC has reiterated its "Buy" rating for Collegium Pharmaceutical (NASDAQ:COLL) and increased its price target to $56, suggesting a 54% upside. This comes despite the company missing quarterly earnings estimates, though revenue grew by 12.9% year-over-year. The consensus among analysts is a "Moderate Buy" with an average target of $53.40.
Collegium Pharmaceutical (NASDAQ:COLL) Given Buy Rating at HC Wainwright
HC Wainwright has reiterated a "Buy" rating for Collegium Pharmaceutical (NASDAQ:COLL) with a $60 price target, suggesting a potential upside of 65%. This comes despite the company missing quarterly EPS estimates and slightly underperforming on revenue, though revenue did increase by 12.9% year-over-year. Insider trading activity was noted with EVP Scott Dreyer selling a significant portion of his holdings.
Collegium Pharmaceutical to acquire AZSTARYS for $650 million
Collegium Pharmaceutical has announced a definitive agreement to acquire AZSTARYS from Corium Therapeutics Holdings, LLC for $650 million in cash, with potential additional milestone payments of up to $135 million. AZSTARYS is a central nervous system stimulant for ADHD patients aged 6 and older, which generated over 760,000 prescriptions in 2025. Collegium plans to fund the acquisition using existing cash and a $300 million delayed draw term loan, expecting significant revenue growth and synergies post-acquisition.
Collegium Pharmaceutical to Acquire AZSTARYS ADHD Franchise
Collegium Pharmaceutical is set to acquire the AZSTARYS ADHD treatment franchise from Corium Therapeutics for $650 million in cash plus potential milestone payments. The acquisition aims to strengthen Collegium's ADHD portfolio, extend revenue streams with patent protection until 2037, and is expected to notably boost adjusted EBITDA and cash flow immediately. The deal will be funded through existing cash and a new term loan, with closing anticipated in the second quarter of 2026.
Collegium (NASDAQ: COLL) to acquire AZSTARYS in $650M ADHD expansion deal
Collegium Pharmaceutical (COLL) announced it will acquire AZSTARYS, an ADHD medicine, for $650 million in cash plus up to $135 million in milestone payments. This strategic acquisition is funded by cash on hand and a delayed draw term loan and is expected to close in Q2 2026. The deal aims to strengthen Collegium’s ADHD portfolio, diversify revenue, and is projected to be immediately accretive to adjusted EBITDA, with AZSTARYS patent protection extending into 2037.
Collegium to Acquire AZSTARYS® from Corium Therapeutics,
Collegium Pharmaceutical, Inc. announced a definitive agreement to acquire AZSTARYS, an ADHD prescription medicine, from Corium Therapeutics for $650 million cash and potential milestone payments. This acquisition aims to strengthen Collegium's position in the ADHD market, diversify its commercial portfolio, and is expected to be immediately accretive to adjusted EBITDA, with patent protection anticipated until 2037. The transaction is projected to close in the second quarter of 2026, funded by existing cash and a $300 million delayed draw term loan.
Collegium ponies up $650M to gain ADHD drug Azstarys from Corium
Collegium Pharmaceutical is acquiring Azstarys, an ADHD drug, from Corium Therapeutics for an upfront payment of $650 million and potential milestone payments. This deal expands Collegium's ADHD market presence by adding Azstarys, which generates over $50 million in annual revenue, to its existing treatment, Jornay PM. The acquisition aims to leverage Collegium's existing commercial infrastructure and diversify its portfolio, including three pain medications.
Collegium Pharmaceutical to Buy AZSTARYS for $650M, Expanding ADHD Franchise Through 2037
Collegium Pharmaceutical announced plans to acquire the ADHD drug AZSTARYS from Corium Therapeutics for $650 million in cash, plus potential contingent payments of up to $135 million. This acquisition will expand Collegium's ADHD franchise by adding a second commercial-stage product alongside Jornay PM, extending the company’s ADHD exclusivity through December 2037. The deal is expected to be immediately accretive to adjusted EBITDA, generate over $50 million in pro forma net revenues from AZSTARYS in H2 2026, and result in over $50 million in cost improvements within 12 months post-closing.
Collegium Pharmaceutical to acquire Corium's ADHD drug for up to $785 million
Collegium Pharmaceutical announced its intention to acquire an ADHD drug from Corium for a total consideration of up to $785 million. The deal, reported by Reuters, involves Collegium Pharmaceutical (COLL) making a significant investment to expand its product portfolio. Further details regarding the terms of the acquisition were not immediately available in the brief announcement.
Fidelity lists 13,976 COLL shares for sale (NASDAQ: COLL)
Fidelity Brokerage Services LLC has filed a Form 144 indicating an intended sale of 13,976 shares of Collegium Pharmaceutical, Inc. (COLL) common stock. These shares are related to restricted stock vesting on March 17, 2026. The filing also notes a previous sale of 6,224 shares by David Dieter on March 9, 2026, for $228,109.60.
Member Spotlight: Collegium Pharmaceutical
Collegium Pharmaceutical, a Massachusetts-based biopharmaceutical company specializing in ADHD and responsible pain management, has partnered with Boston Legacy FC. This collaboration aims to support professional women's soccer in Boston and create a more inclusive fan experience, including the development of a sensory room at White Stadium. The initiative reflects Collegium's commitment to community investment and fostering healthier people through stronger communities.
Collegium (NASDAQ: COLL) EVP sells 6,224 shares under 10b5-1 plan
David Dieter, EVP & General Counsel of Collegium Pharmaceutical (NASDAQ: COLL), sold 6,224 shares of common stock at $36.65 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan established on December 5, 2025. Following the sale, Dieter directly holds 91,047 shares of the company.
WINTON GROUP Ltd Purchases Shares of 65,345 Collegium Pharmaceutical, Inc. $COLL
WINTON GROUP Ltd recently acquired a new stake of 65,345 shares in Collegium Pharmaceutical, Inc. (NASDAQ:COLL), valued at approximately $2.29 million. Concurrently, Collegium Pharmaceutical's EVP Scott Dreyer sold 49,976 shares for about $2.02 million, reducing his stake by over 40%. The company recently missed quarterly earnings expectations and has a "Moderate Buy" consensus rating from analysts with a target price of $53.
Victory Capital Management Inc. Cuts Stock Position in Collegium Pharmaceutical, Inc. $COLL
Victory Capital Management Inc. reduced its stake in Collegium Pharmaceutical, Inc. by 5.7% in the third quarter, now holding 479,672 shares valued at approximately $16.8 million. Concurrently, EVP Scott Dreyer sold a significant portion of his holdings, decreasing his position by over 41%. Analyst sentiment for Collegium Pharmaceutical is currently a "Moderate Buy" with an average target price of $53.00, despite some recent downgrades to "Hold."
Assessing Collegium Pharmaceutical (COLL) Valuation After Recent Share Price Weakness
Collegium Pharmaceutical (COLL) has experienced recent stock price weakness, with declines over the past week, month, and three months, despite annual revenue of $780.567m and net income of $62.87m. Simply Wall St's analysis suggests the stock is 30.6% undervalued, with a fair value of $53.67 compared to its current trading price of $37.27, based on its differentiated pain portfolio and industry trends favoring safer opioid options. However, this valuation is subject to risks like potential generic competition and pricing pressure on opioid therapies.
Assessing Collegium Pharmaceutical (COLL) Valuation After Recent Share Price Weakness
Collegium Pharmaceutical (COLL) has experienced recent stock price weakness, with declines over the past week, month, and three months, despite long-term positive returns. The article suggests the stock, currently trading at $37.27, is undervalued with a fair value pegged at $53.67, driven by its differentiated pain portfolio and favorable regulatory trends for safer opioid options. Investors are advised to consider the potential generic competition and pricing pressures as key risks before making investment decisions.
Jefferies Financial Group Inc. Takes $4.43 Million Position in Collegium Pharmaceutical, Inc. $COLL
Jefferies Financial Group Inc. has established a new position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL), acquiring 126,565 shares valued at approximately $4.43 million in the third quarter, representing about 0.40% of the company. This comes as Collegium Pharmaceutical missed its quarterly EPS estimates but saw a 12.9% year-over-year revenue increase. Analysts hold a "Moderate Buy" consensus on the stock with an average price target of $53, significantly higher than its current trading price of around $37.27.
(COLL) Volatility Zones as Tactical Triggers
This article from Stock Traders Daily discusses Collegium Pharmaceutical Inc. (NASDAQ: COLL) and provides an AI-generated analysis of its volatility zones as tactical triggers. It highlights weak near and mid-term sentiment challenging a positive long-term outlook, with a breakdown underway and elevated downside risk. The analysis includes specific trading strategies (Position, Momentum Breakout, Risk Hedging) with entry, target, and stop-loss levels, alongside multi-timeframe signal analysis and real-time AI-generated signals for support and resistance.
Scott Dreyer Sells 49,976 Shares of Collegium Pharmaceutical (NASDAQ:COLL) Stock
Collegium Pharmaceutical (NASDAQ:COLL) EVP Scott Dreyer sold 49,976 shares of the company's stock on March 3rd at an average price of $40.41, totaling over $2 million, and reducing his direct ownership by 41.05%. This sale occurred shortly after the company reported quarterly earnings per share and revenue that missed analyst estimates, causing the stock to drop by 5.9%. Despite the recent dip and insider selling, analysts maintain a "Moderate Buy" rating for COLL with an average price target of $53.00, and institutional investors like Vanguard and Renaissance Technologies have significant holdings.
Insider Sell: Scott Dreyer Sells 49,976 Shares of Collegium Phar
Scott Dreyer, Executive Vice President & Chief Commercial Officer at Collegium Pharmaceutical Inc (COLL), sold 49,976 shares of the company on March 3, 2026. This transaction brings his total ownership to 71,770 shares. Over the past year, Dreyer has sold a total of 148,306 shares with no purchases, aligning with a broader trend of 22 insider sells and no buys at Collegium Pharmaceutical Inc during the same period.
Collegium to Present New Real-World Data at PainConnect 2026
Collegium Pharmaceutical, Inc. announced it will present two posters featuring real-world data from its pain medication portfolio at PainConnect 2026, the American Academy of Pain Medicine’s Annual Meeting. These presentations aim to provide clinical insights into how therapies perform in real-world settings, informing pain treatment and clinical practice. The company emphasizes its commitment to generating evidence to inform everyday medical practice and ongoing scientific dialogue in pain management.
Collegium to Present New Real-World Data at PainConnect 2026
Collegium Pharmaceutical, Inc. announced it will present two posters featuring real-world data from its pain medication portfolio at PainConnect 2026, the American Academy of Pain Medicine’s Annual Meeting. The presentations will offer clinical insights, demonstrating the company's commitment to generating evidence for everyday practice in pain management. This event takes place in Salt Lake City, Utah from March 5-8, 2026.
Quantbot Technologies LP Has $1.79 Million Position in Collegium Pharmaceutical, Inc. $COLL
Quantbot Technologies LP significantly increased its stake in Collegium Pharmaceutical, Inc. by 380.2%, now holding 51,236 shares valued at $1.79 million. Despite this, company insiders, including EVP Scott Dreyer and Director Rita J. Balice-Gordon, recently sold shares. Analysts maintain a "Moderate Buy" rating with an average price target of $53 for Collegium Pharmaceutical.
